News and Updates

Our Statement on Deceased Donor Islet Cell Availability & The ISLET Act Curing type 1 diabetes (T1D) is Breakthrough T1D’s number one priority. As the leading global T1D research and advocacy organization, we are currently funding over $450 million in cures research in 23 countries. Everything we do is focused on making cures happen for the T1D […]

One of our most promising avenues toward cures for type 1 diabetes (T1D) is cell therapies. Cell therapies replace destroyed beta cells with functional, insulin-producing cells to restore insulin therapy independence. Right now, there are nearly a dozen cell therapies in clinical testing—and OPF-310 is one of them. OPF-310 cells are derived from porcine (pig) […]

Breakthrough T1D had the pleasure of speaking with Patti Columbe, a participant in Vertex’s pivotal trial for the manufactured islet therapy zimislecel (formerly VX-880). Patti has been living with type 1 diabetes (T1D) for nearly 39 years. This is one of the most exciting T1D trials in terms of getting us closer to cures for […]

A new Breakthrough T1D-funded study finds that people with T1D and their caregivers are largely willing to try advanced new T1D therapies.

Hy-Vee has been a trusted partner of Breakthrough T1D since 1988, raising nearly $20 million through corporate and store events.

Breakthrough T1D’s newest publication outlines a roadmap for beta cell replacement therapies for type 1 diabetes.

Hypoimmune (HIP) islets are making insulin, without immunosuppressants, in the first person treated with type 1 diabetes.

Breakthrough T1D was in Chicago, IL for ADA 2025. Here we report on the latest advancements in cures for type 1 diabetes.

Breakthrough T1D, Breakthrough T1D Canada, and the Stem Cell Network (SCN) have partnered to support cell therapy research in Canada.

The Medical Affairs team is working to ensure the clinical adoption of forthcoming manufactured cell therapies.